Los Angeles Capital Management LLC Takes Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Los Angeles Capital Management LLC purchased a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 20,033 shares of the specialty pharmaceutical company's stock, valued at approximately $625,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of SUPN. Commonwealth Equity Services LLC raised its stake in shares of Supernus Pharmaceuticals by 3.6% in the second quarter. Commonwealth Equity Services LLC now owns 10,195 shares of the specialty pharmaceutical company's stock worth $273,000 after acquiring an additional 350 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Supernus Pharmaceuticals by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company's stock worth $61,000 after buying an additional 352 shares in the last quarter. Covestor Ltd boosted its position in Supernus Pharmaceuticals by 15.3% in the 1st quarter. Covestor Ltd now owns 2,702 shares of the specialty pharmaceutical company's stock valued at $92,000 after buying an additional 358 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Supernus Pharmaceuticals by 97.1% in the 3rd quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company's stock valued at $25,000 after buying an additional 398 shares during the period. Finally, Louisiana State Employees Retirement System raised its position in shares of Supernus Pharmaceuticals by 2.2% during the second quarter. Louisiana State Employees Retirement System now owns 27,700 shares of the specialty pharmaceutical company's stock worth $741,000 after acquiring an additional 600 shares during the last quarter.

Wall Street Analyst Weigh In

Several research firms recently issued reports on SUPN. StockNews.com upgraded Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Wednesday, August 7th. Piper Sandler reaffirmed a "neutral" rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Finally, Cowen reissued a "buy" rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th.

Insiders Place Their Bets

In related news, Director Georges Gemayel sold 14,213 shares of the business's stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $36.62, for a total value of $520,480.06. Following the completion of the transaction, the director now directly owns 13,315 shares in the company, valued at approximately $487,595.30. The trade was a 51.63 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jack A. Khattar sold 125,000 shares of the stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $36.68, for a total value of $4,585,000.00. Following the sale, the chief executive officer now directly owns 926,172 shares of the company's stock, valued at approximately $33,971,988.96. The trade was a 11.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 154,213 shares of company stock worth $5,660,180. Company insiders own 9.30% of the company's stock.

Supernus Pharmaceuticals Stock Down 1.7 %

Shares of Supernus Pharmaceuticals stock traded down $0.61 during trading on Friday, reaching $35.57. 403,290 shares of the company were exchanged, compared to its average volume of 414,677. The business has a 50-day moving average price of $33.35 and a 200-day moving average price of $30.92. The firm has a market capitalization of $1.96 billion, a price-to-earnings ratio of 33.24 and a beta of 0.86. Supernus Pharmaceuticals, Inc. has a twelve month low of $25.53 and a twelve month high of $39.37.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last posted its earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.25. The company had revenue of $175.70 million during the quarter, compared to analyst estimates of $157.35 million. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The company's revenue for the quarter was up 14.2% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.29) EPS. On average, equities research analysts forecast that Supernus Pharmaceuticals, Inc. will post 2.37 EPS for the current fiscal year.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.